March 4, 2009

A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients

Key Points

Key points are not available for this paper at this time.

Abstract

The magnitude of the predicted changes in exposure with the covariates studied minimizes the necessity for dose adjustment in any of these subpopulations.

Ask AI

Helpful

Bookmark

Ask AI

Helpful

Bookmark

Cite This Study

Houk et al. (Wed,) studied this question.

synapsesocial.com/papers/69daaf8685037e71b2684983 https://doi.org/https://doi.org/10.1158/1078-0432.ccr-08-1893

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A three-step approach combining bayesian regression and NONMEM population analysis: Application to midazolam1991 · 173 citations
2Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese2007 · 168 citations
3Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane2008 · 484 citations
4Sunitinib in Patients With Metastatic Renal Cell Carcinoma2006 · 1,228 citations
5Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma2007 · 5,759 citations